Xeris Biopharma reportedly rises on Lundbeck takeover interest
XERS•Xeris Biopharma shares rose 2.8% to $10.08 after Lundbeck reportedly expressed interest in acquiring the company. Lundbeck has been working with advisers to explore a takeover, the report said.
1. Takeover interest reported
Lundbeck has expressed interest in acquiring Xeris Biopharma and has been working with advisers to explore a takeover, the report said, citing people familiar with the matter. The companies did not immediately respond to requests for comment. Xeris shares were up 27.9% year to date through the prior close.
